Hepatitis B Virus: From Diagnosis to Treatment
Abstract Hepatitis B infection is still a global concern progressing as acute-chronic hepatitis, severe liver failure, and death. The infection is most widely transmitted from the infected mother to a child, with infected blood and body fluids. Pregnant women, adolescents, and all adults at high risk of chronic infection are recommended to be screened for hepatitis B infection. The initial analysis includes serological tests that allow differentiation of acute and chronic hepatitis. Molecular assays performed provide detection and quantification of viral DNA, genotyping, drug resistance, and precore/core mutation analysis to confirm infection and monitor disease progression in chronic hepatitis B patients. All patients with chronic hepatitis B should be treated with antiviral medications and regularly monitored for efficient treatment. The current treatment is based on nucleos(t)ide analogs and pegylated interferons that save lives by decreasing liver cancer death, liver transplant, slow or reverse the progression of liver disease as well as the virus infectivity..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:69 |
|---|---|
| Enthalten in: |
Polish journal of microbiology - 69(2020), 4 vom: 01. Jan., Seite 391-399 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
GUVENIR, MERYEM [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
© 2020 Meryem Guvenir et al., published by Sciendo |
|---|
| doi: |
10.33073/pjm-2020-044 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
GRUY008615004 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | GRUY008615004 | ||
| 003 | DE-627 | ||
| 005 | 20230813114450.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230813s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.33073/pjm-2020-044 |2 doi | |
| 035 | |a (DE-627)GRUY008615004 | ||
| 035 | |a (DE-B1597)pjm-2020-044-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 570 |q VZ |
| 084 | |a 12 |2 ssgn | ||
| 084 | |a BIODIV |q DE-30 |2 fid | ||
| 100 | 1 | |a GUVENIR, MERYEM |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hepatitis B Virus: From Diagnosis to Treatment |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2020 Meryem Guvenir et al., published by Sciendo | ||
| 520 | |a Abstract Hepatitis B infection is still a global concern progressing as acute-chronic hepatitis, severe liver failure, and death. The infection is most widely transmitted from the infected mother to a child, with infected blood and body fluids. Pregnant women, adolescents, and all adults at high risk of chronic infection are recommended to be screened for hepatitis B infection. The initial analysis includes serological tests that allow differentiation of acute and chronic hepatitis. Molecular assays performed provide detection and quantification of viral DNA, genotyping, drug resistance, and precore/core mutation analysis to confirm infection and monitor disease progression in chronic hepatitis B patients. All patients with chronic hepatitis B should be treated with antiviral medications and regularly monitored for efficient treatment. The current treatment is based on nucleos(t)ide analogs and pegylated interferons that save lives by decreasing liver cancer death, liver transplant, slow or reverse the progression of liver disease as well as the virus infectivity. | ||
| 700 | 1 | |a ARIKAN, AYSE |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Polish journal of microbiology |d Sciendo, 2004 |g 69(2020), 4 vom: 01. Jan., Seite 391-399 |h Online-Ressource |w (DE-627)GRUY008436681 |w (DE-600)2234080-4 |w (DE-576)281308624 |x 2544-4646 |7 nnns |
| 773 | 1 | 8 | |g volume:69 |g year:2020 |g number:4 |g day:01 |g month:01 |g pages:391-399 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.33073/pjm-2020-044 |z kostenfrei |3 Volltext |
| 912 | |a GBV_GRUY | ||
| 912 | |a FID-BIODIV | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 69 |j 2020 |e 4 |b 01 |c 01 |h 391-399 | ||